Clinical Trial Update: B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults [Phase 4]

View source ↗

Summary

Phase 4 double-blind switch study comparing B/F/TAF to Atripla in HIV-1 infected adults; terminated with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
• B/F/TAF (emtricitabine/tenofovir alafenamide/cobicistat-darunavir)

Snippet

Sponsor: University of Alberta | Conditions: HIV-1-infection | Phase 4 | Status: TERMINATED | Results posted: 2022-12-14